

The Efficacy and Safety of OM-89 in Patients With Recurrent Chronic Prostatitis/Chronic Pelvic Pain Syndrome

NCT06345014

Status	RECRUITING
Phase	Phase 4
Sponsor	AJU Pharm Co., Ltd.
Enrollment	332 participants

Key Eligibility Criteria

Inclusion (4)

- Male adults aged e19 to d55 at the time of obtaining the written consent
- Those who have t pain or discomfort in the pelvic or genital area
- NIH-CPSI (the National Institutes of Health Chronic Prostatitis Symptom Index) e 15 in total score
- voluntarily signed the informed consent form to participate in this study

Exclusion (4)

- Prostate specific antigen (PSA) e 4.0 ng/ml at Visit 1 (screening)
- Received a prostate biopsy, surgery, or treatment within 12 weeks before Visit 1 (screening)
- Past or current medical history as Herpes infection treatment within 1 year before the Screening, Treatment for genital infections or sexually transmitted diseases and History of urogenital tumors.
- Those who have a medication history of the drugs (Drugs or health functional food, Health functional foods that affect prostate function etc) or have a plan to receive them during the study at Visit 1

Locations (1 total)

AJU Pharm Co., Ltd., Seoul, South Korea